Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 9/20 | 0.40 |
| ▸ | NPY1R | P25929 | 5/20 | 0.40 |
| ▸ | NPY2R | P49146 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368171 | 1.00 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL1521349 | 1.00 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL2184148 | 0.90 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL1521599 | 0.90 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL1521366 | 0.89 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL18159136 | 0.86 | DPP7 (0.47) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL1004635 | 0.86 | DPP7 (0.47) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL1521379 | 0.86 | DPP7 (0.47) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL23626315 | 0.85 | DPP7 (0.61) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL23610947 | 0.85 | DPP7 (0.61) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0545991-B1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE ANDERS (SE) | 1998-12-02 | — | — | EP | claimed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | claimed |
| EP-3987003-A1 | SYSTEMS AND METHODS FOR FABRICATING A MICROCHANNEL VASCULAR NETWORK DEVICE AND SEEDING A MICROCHANNEL | 3D Biolabs, LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210071145-A1 | SYSTEMS AND METHODS FABRICATING A MICROCHANNEL VASCULAR NETWORK DEVICE AND SEEDING A MICROCHANNEL | 3D BIOLABS, LLC | 2021-03-11 | — | — | US | disclosed |
| WO-2020257539-A1 | SYSTEMS AND METHODS FOR FABRICATING A MICROCHANNEL VASCULAR NETWORK DEVICE AND SEEDING A MICROCHANNEL | 3D BIOLABS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20050265989-A1 | Non-toxic purification and activation of prothrombin and use thereof | KALD FISK AS (NO) | 2005-12-01 | — | — | US | disclosed |
| EP-0545991-B1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE ANDERS (SE) | 1998-12-02 | — | — | EP | disclosed |
| US-5087564-A | Preferential cleavage of an e coli rec a fusion protein at the clu-ser junction site of a heterologous peptide | MONSANTO COMPANY (US) | 1992-02-11 | — | — | US | disclosed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0207044-A1 | Release of peptides from polypeptides | Monsanto Company (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |